Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Starr

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
The Journal of Clinical Investigation|February 5, 2020
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapyBalamayoora Theivanthiran, Kathy S Evans, Nicholas C DeVito, et al.
The Oncologist|April 8, 2021
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)Toni K Choueiri, Yousef Zakharia, Sumanta Pal, et al.
The Journal of Clinical Investigation|August 9, 2013
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironmentBrent A Hanks, Alisha Holtzhausen, Katherine S Evans, et al.
Cell|August 8, 2025
Vagal blockade of the brain-liver axis deters cancer-associated cachexiaAliesha Garrett, Naama Darzi, Ashlesha Deshmukh, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
The Journal of Clinical Investigation|February 5, 2020
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapyBalamayoora Theivanthiran, Kathy S Evans, Nicholas C DeVito, et al.
The Oncologist|April 8, 2021
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)Toni K Choueiri, Yousef Zakharia, Sumanta Pal, et al.
The Journal of Clinical Investigation|August 9, 2013
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironmentBrent A Hanks, Alisha Holtzhausen, Katherine S Evans, et al.
Cell|August 8, 2025
Vagal blockade of the brain-liver axis deters cancer-associated cachexiaAliesha Garrett, Naama Darzi, Ashlesha Deshmukh, et al.
Pageof 2